Gene · 6188
RPS3: ribosomal protein S3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPS3: ribosomal protein S3. Genes, record 6188. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6188
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P23396 | Small ribosomal subunit protein uS3 | 243 | 190 | Ensembl, GeneID, HGNC |
Source UniProt
Patents56
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62142 | P23396 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62143 | P23396 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62144 | P23396 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 15635 | P23396 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 18757 | P23396 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 7699 | P23396 | Espacenet |
| WO 2025181335 A1 | 2025-09-04 | 14 | P23396 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 18757 | P23396 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 15635 | P23396 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 7699 | P23396 | Espacenet |
1 to 10 of 56
See all 56 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants998
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPS3 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| R35GM136323 | Dissecting the Mechanisms of Regulation and Quality Control in Ribosome Assembly and the Consequences of their Failure | 5 | 2025 |
| T32CA009110 | Training in Areas Fundamental to Cancer Research | 5 | 2025 |
| R01AI092531 | Population Genomic Analysis of Gut Microbial Colonization in Premature Infants | 4 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 3 | 2025 |
| P20GM103427 | Nebraska Research Network in Functional Genomics | 3 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 3 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
| P40OD018537 | Bloomington Drosophila Stock Center at Indiana University | 3 | 2025 |
1 to 10 of 998Source NIH's project files
See all 998 nih grantsPapers1,784
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A ribosomal protein-rich tumor cell supernatant as a potent inducer of macrophage polarization for synergistic antitumor chemotherapy. | Biomaterials | 2027 | 42531894 | PubTator, text mining | PubMed |
| Exploring Molecular Pathways in Metastasis of Breast Cancer Cells to the Brain: Insights from Gene Expression Analysis and Cellular Origins. | J Microsc Ultrastruct | 2026 | 42824931 | PubTator, text mining | PubMed |
| Macrophage Differentiation Selectively Downregulates RPS15A While Preserving RPL13A and RPL17 Expression in THP-1-Derived Macrophages. | J Cardiovasc Dev Dis | 2026 | 42783057 | PubTator, text mining | PubMed |
| The spindle-associated antisense RNA ARHGEF17-AS1 functionally contributes to mitotic spindle integrity. | Cell Rep | 2026 | 42771527 | PubTator, text mining | PubMed |
| Differential analysis of urinary stable downregulated proteins in male patients after colorectal cancer surgery. | Front Oncol | 2026 | 42707234 | PubTator, text mining | PubMed |
| Ribosomal protein S3: a critical regulator of human disease mechanisms. | Biosci Rep | 2026 | 42682010 | PubTator, text mining | PubMed |
| Targeting SRPK3 Attenuates Cardiac Hypertrophy and Heart Failure by Improving Mitochondrial Bioenergetics through mRNA Splicing and Decay. | Research (Wash D C) | 2026 | 42638823 | PubTator, text mining | PubMed |
| LAPTM4B promotes gefitinib resistance and tumor stemness in non-small cell lung cancer by stabilizing RPS3 through inhibiting its ubiquitination. | Biochim Biophys Acta Mol Cell Res | 2026 | 42612828 | PubTator, text mining | PubMed |
| Heat shock protein family D member 1 (HSPD1) modulates ribosome-related pathways and protein synthesis in lung adenocarcinoma. | Mol Cell Biochem | 2026 | 42573975 | PubTator, text mining | PubMed |
| Ribosomal Proteins in Blood Exosomes as Markers of an Unfavorable Prognosis in Patients with Breast Cancer. | Asian Pac J Cancer Prev | 2026 | 42522810 | PubTator, text mining | PubMed |
1 to 10 of 1,784
See all 1,784 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6188
GET https://conductscience.org/api/genes/v1/6188/patents?page=2